Yeztugo, a twice-yearly shot, could be the catalyst for stopping a recent spike in new HIV diagnoses. It's now available in ...

Milestone Pharmaceuticals Inc. is a strong buy after a 37% drop post-Cardamyst FDA approval. Click for this updated look at ...

Labour accused of ripping up "basic principle" Britons should not face higher taxes for improving their homes or gardens while... The alleged victim suffered significant injuries to his face, neck and ...